Replies to post #489826 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

In the last month NVCR has gone from just over $75 to just under it. Lot of movement but really gone nowhere.

Since they launched as public company 8 years ago NVCR has seen the PPS rise from $21 to $75. They have received 3 FDA approvals. Reimbursement in Germany, Austria, Israel. Japan and others. They have numerous trials for other indications well under way (including several combo trials with Merck).

Since they became public company 21 years ago NWBO has seen their PPS drop from $1,2000 to $0.69. They have 0 approved drugs. They are not sponsoring any active trials other than the current P3 that launched well over a decade ago (which oddly enough has still not reached primary completion). They would not even provide DCVax-L for UCLA to run the Merck combo trial.